Gilead’s Elvitegravir Phase III Could Face Challenges With Novel HIV Comparator
This article was originally published in The Pink Sheet Daily
Executive Summary
Integrase inhibitor will likely need to be compared to active control such as investigational maraviroc or raltegravir in Phase III, firm reports.